Jacqueline Armstrong
Adult Health · Chambersburg, PANPI 1215408737
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,456 of the $39,600 with a category attached, or 87.0%. AbbVie accounts for 96.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $17,845 and has fallen 91.0% since, to $1,612 in 2024. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $202.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$38K
- Lilly USA, LLC$248
- Merck$165
- AstraZeneca$135
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$121
- E.r. Squibb & Sons, L.L.C.$95
- plus $780 from 14 others
What the payments were for
- Speaking & faculty fees$34,45687%
- Travel & lodging$2,0985%
- Food & beverage$3,0458%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 110 | $38,055 |
| Lilly USA, LLC | 15 | $248 |
| Merck | 8 | $165 |
| AstraZeneca(2 entities) | 8 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $121 |
| E.r. Squibb & Sons, L.L.C. | 5 | $95 |
| Boehringer Ingelheim | 6 | $95 |
| Amarin Pharma, Inc. | 4 | $82 |
| GSK | 5 | $82 |
| Johnson & Johnson | 5 | $75 |
| Pfizer | 5 | $72 |
| Eisai Inc. | 2 | $72 |
| Amgen | 4 | $70 |
| Novo Nordisk | 4 | $68 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Novartis | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,600 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 54 | $62,331 |
| OzempicSemaglutide | 35 | $47,299 |
| EliquisApixaban | 44 | $39,950 |
| MounjaroTirzepatide | 12 | $29,732 |
| FarxigaDapagliflozin Propanediol | 20 | $24,087 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,848 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,440 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,408 |
| Ezetimibe | 78 | $2,161 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,450 |
| SynthroidLevothyroxine Sodium | 22 | $1,415 |
| Rosuvastatin Calcium | 41 | $1,281 |
| Pantoprazole Sodium | 67 | $1,220 |
| Omeprazole | 75 | $1,137 |
| Atorvastatin Calcium | 91 | $1,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $95 | $62,33154 claims |
| Novo NordiskOzempic | $68 | $47,29935 claims |
| PfizerEliquis | $72 | $39,95044 claims |
| Lilly USA, LLCMounjaro | $248 | $29,73212 claims |
| AstraZenecaFarxiga | $135 | $24,08720 claims |
| AbbVieSynthroid | $38,055 | $1,41522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Chambersburg
- Beth SandyPhiladelphia$924K
- Jennifer MondilloSchwenksville$396K
- Diane NewmanPhiladelphia$343K
- Elizabeth FaustDouglassville$342K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
- Catherine HoldsworthPhiladelphia$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.